Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

Here we show that an orally administered adeno-associated viral vector leads to persistent ... selected to receive AAVlac (a recombinant AAV vector expressing ß-galactosidase 18) or PBS vehicle.

Nanoneedle technology offers the capability to simultaneously quantify titers of true, full viral genomes and a range of ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

Adeno-associated viral (AAV) vectors in particular have high transduction rates and reduced toxicity concerns compared to other viral vectors. However, these delivery vehicles present some application ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

(NYSE: BIO and BIO.B), announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adenoassociated virus (AAV) serotypes 2 and 8 ... reproducible data for reliable assessment for critical ...

The study presents a potential alternative to adeno-associated virus (AAV)-mediated gene therapy ... researchers used a lentiviral vector to deliver gene therapy to five patients with hemophilia ...

However, SV-AUC was better than SEC-MALS in creating a detailed "map" of the distribution of the genetic and viral particles in the AAV vector. The study suggested that "SEC-MALS could be ...

Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint ...